Barriers and Strategies: A Review of Access to Affordable Multi-Drug Resistant Tuberculosis Medication in China

References

• World Health Organization. Rapid Communication: Key Changes to Treatment of Multidrug‑and Rifampicin‑resistant Tuberculosis (MDR/RR‑TB). Geneva: World Health Organization; 2018.
   Google Scholar
• World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug‑resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization; 2013.
   Google Scholar
• Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6):645‐662. doi:10.5588/ijtld.18.0622
   Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2019 Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf. Accessed 86 2020.
   Google Scholar
• Lonnroth K, Glaziou P, Weil D, et al. Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention. PLoS Med. 2014;11(9):e1001693. doi:10.1371/journal.pmed.100169325243782
   PubMed Web of Science ®Google Scholar
• Richter LM, Lonnroth K, Desmond C, et al. Economic support to patients in HIV and TB grants in rounds 7 and 10 from the global fund to fight AIDS, tuberculosis and malaria. PLoS One. 2014;9(1):e86225. doi:10.1371/journal.pone.008622524489702
   PubMed Web of Science ®Google Scholar
• Herbert N, Sharma V, Masham BS, et al. Concrete action now: UN high-level meeting on tuberculosis. Lancet Infect Dis. 2018;18(7):709–710. doi:10.1016/S1473-3099(18)30171-329580817
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tuberculosis country profiles. Available from: https://www.who.int/tb/country/data/profiles/en/. Accessed 68, 2020.
   Google Scholar
• Jiang J, Lucas H, Long Q, et al. The effect of an innovative financing and payment model for tuberculosis patients on health service utilization in China: evidence from Hubei Province of China. Int J Environ Res Public Health. 2019;16:14. doi:10.3390/ijerph16142494
   Web of Science ®Google Scholar
• Ren C, Lin H, Yang S. Epidemic characteristics of tuberculosis and multidrug-resistant strains and strategies. Chinese J Lung Dis. 2019;3(269274):. doi:10.3877/cma.j.issn.1674-6902.2019.03.001
   Google Scholar
• Long Q, Qu Y, Lucas H. Drug-resistant tuberculosis control in China: progress and challenges. Infect Dis Poverty. 2016;5:9. doi:10.1186/s40249-016-0103-326822738
   PubMed Web of Science ®Google Scholar
• TB Prevention and Control Center of China CDC. The Comprehensive TB Control Model: Baseline Survey Report. in Chinese. Beijing: China CDC;2013.
   Google Scholar
• Wang L, Nunn PP, Xu S Achievements and Challenges in Tuberculosis Control in Modern China.1st Edition. Beijing: People’s Medical Publishing House; 2016. (in Chinese)
   Google Scholar
• Xin YJ, Xiang L, Jiang JN, et al. The impact of increased reimbursement rates under the new cooperative medical scheme on the financial burden of tuberculosis patients. Infect Dis Poverty. 2019;8(1):67. doi:10.1186/s40249-019-0575-z31370909
   PubMed Web of Science ®Google Scholar
• The Ministry of Human Resources and Social Security. The national reimbursement list of the basic health insurance (2017 edition). Available from: http://www.mohrss.gov.cn/SYrlzyhshbzb/dongtaixinwen/buneiyaowen/201702/t20170223_266787.html. Accessed 66, 2020. (in Chinese)
   Google Scholar
• World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Available from: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1. Accessed 67, 2020.
   Google Scholar
• Frontières MS. MSF warns high prices of tuberculosis drugs to restrict people’s access to best drug-resistant TB treatment. (content current as of 2018-10-20). Available from: https://msf-seasia.org/news/18360. Accessed 68, 2020.
   Google Scholar
• The National Healthcare Security Administration of China. The announcement of the inclusion of the novel medicines in the national basic health insurance medicines reimbursement list through the 2019 national medicines price negotiation. No. 65 document of 2019. (content current as of 2019-11-28). Available from: http://www.nhsa.gov.cn/art/2019/11/28/art_37_2050.html. Accessed 68, 2020. (in Chinese)
   Google Scholar
• Wang L, Cheng B. Theory and Practice of Financing and Provider Payment Reform of Tuberculosis. in Chinese. Beijing: People’s Health Publishing House; 2019:p49.
   Google Scholar
• Xu C, Ma W, Zhang C, et al. Analysis of the reimbursement of MDR-TB expenditures by different basic health insurance programs in China. Chn J Prev Med. 2014;7:633–635. doi:10.16506/j.1009-6639.2014.07.012;.
   Google Scholar
• Wang G, Sleigh A, Zhou G, et al. Non-biologic risk factors of pulmonary tuberculosis among adults in Henan: a case-control study. Chin J Epidemiol. 2005;2:20–24.
   Google Scholar
• Yang J, Liu M, Yang F, et al. Analysis of influencing factors of tuberculosis incidence using a two-level logistic regression model. Chin J Health Stat. 2009;4:374–376. (in Chinese)
   Google Scholar
• China CDC and Peking University. Analysis results of the national survey of the economic burden of TB patients. Unpublished report. (in Chinese)
   Google Scholar
• Sotgiu G, Pontali E, Migliori GB. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J. 2015;45(1):25–29. doi:10.1183/09031936.0014501425552734
   PubMed Web of Science ®Google Scholar
• Weda MHJ, Vervloet M, et al. Study on Off-Label Use of Medicinal Products in the European Union. Belgium, Brussels: European Union; 2017.
   Google Scholar
• Sachs RE, Ginsburg PB, Goldman DP. Encouraging new uses for old drugs. JAMA. 2017;318(24):2421–2422. doi:10.1001/jama.2017.1753529204602
   PubMed Web of Science ®Google Scholar
• Wu Q “Why do I treat a hospice cancer patient with Morphine?”-the first case of prosecution of morphine related medical care. (content current as of 2017-09-24). Available from: http://www.china-pharmacy.com/2/232/26198.html. Accessed 68, 2020. (in Chinese)
   Google Scholar
• Guangdong Pharmaceutical Association. Expert’s consensus on unregistered medicines use 2010. (content current as of 2015-01-22). Available from: http://sinopharmacy.com.cn/download/1.html. Accessed 68, 2020. (in Chinese)
   Google Scholar
• Langedijk J, Whitehead CJ, Slijkerman DS, et al. Extensions of indication throughout the drug product lifecycle: a quantitative analysis. Drug Discov Today. 2016;21(2):348–355. doi:10.1016/j.drudis.2015.11.00926657087
   PubMed Web of Science ®Google Scholar
• Nayroles G, Frybourg S, Gabriel S, et al. Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. J Mark Access Health Policy. 2017;5(1):1298190. doi:10.1080/20016689.2017.129819028740616
   PubMedGoogle Scholar
• The Medicines Patent and License Database. MedsPaL. Available from: https://www.medspal.org/?country_name%5B%5D=China&page=1. Accessed 68, 2020.
   Google Scholar
• Smieliauskas F, Sharma H, Hurley C, et al. State insurance mandates and off-label use of chemotherapy. Health Econ. 2018;27(1):e55e70. doi:10.1002/hec.3537
   Web of Science ®Google Scholar
• Johnson PE Pharmaceutical reimbursement: an overview. Am j Health-System Pharm. Suppl.2008;1:S4.:.
   Google Scholar
• L’Agence nationale de sécurité du médicament et des produits de santé. Available from: https://www.ansm.sante.fr/L-ANSM/Une-agence-d-expertise/L-ANSM-agence-d-evaluation-d-expertise-et-de-decision/(offset)/0. Accessed 68, 2020 (in French)
   Google Scholar
• Emmerich J, Dumarcet N, Lorence A. France’s new framework for regulating off-label drug use. N Engl J Med. 2012;367(14):1279–1281. doi:10.1056/NEJMp120834723034018
   PubMed Web of Science ®Google Scholar
• Verbaanderd C, Rooman I, Meheus L, et al. On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients. Front Pharmacol. 2019;10:1664. doi:10.3389/fphar.2019.0166432076405
   PubMed Web of Science ®Google Scholar
• US FDA. Frequently asked questions on patents and exclusivity. (content current as of 2018-05-02). Available from: https://www.fda.gov/drugs/development-approval-process-drugs/frequently- asked-questions-patents-and-exclusivity#howlongexclusivity. Accessed 68, 2020.
   Google Scholar
• Consumer News and Business Channel. Biontech and Pharma. Gilead’s potential coronavirus treatment gets FDA’s orphan drug label. (content current as of 2020-03-24). Available from: https://www.cnbc.com/2020/03/24/gileads-potential-coronavirus-treatment-gets-fdas-orphan-drug-label.html. Accessed 68, 2020.
   Google Scholar
• European Commission. Enterprise and industry directorate-general. Guidance on a new therapeutic indication for a well-established substance. Belgium, Brussels: european Commission; 2007. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/10%2520_5_%2520guideline_11-2007_en.pdf. Accessed 68, 2020.
   Google Scholar
• Copenhagen Economics. Directorate-general for internal market, industry, entrepreneurship and SMEs. Directorate f — innovation and advanced manufacturing. Unit GROW-F.5 — intellectual property and fight against counterfeiting. Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe. Belgium, Brussels: European Commission; 2018 Available from: https://ec.europa.eu/health/sites/health/files/human-use/docs/pharmaceuticals_incentives_study_en.pdf. Accessed 68, 2020.
   Google Scholar
• National Medical Products Administration. The general office of national medical products administration publicly solicited opinions on medicines registration regulation (revised version). (content current as of 2017-10-23). Available from: http://www.nmpa.gov.cn/WS04/CL2095/229342.html. Accessed 68, 2020. (in Chinese)
   Google Scholar
• National Medical Products Administration. The general office of National Medical Products Administration publicly solicited opinions on Implementation Regulation of Medicines Test Data Protection (2018 draft, call for comments). (content current as of 2018-04-25). Available from: http://www/nmpa/gov.cn/WS04/CL2051/227856.html. Accessed 8 June 2020 (in Chinese)
   Google Scholar
• China’s open law platform. The 2019 regulations for the implementation of the drug administration law. Available from: http://open.pkulaw.cn/FullText/ViewFullText?library=chl&gid=330916&match=Exact. Accessed 68, 2020. (in Chinese)
   Google Scholar
• National Science and Technology Major Project. Major projects. Available from: http://www.nmp.gov.cn/zxjs/. Accessed 68, 2020. (in Chinese)
   Google Scholar
• Sun YMX, Li P, et al. National science and technology major projects for new drug development: A new engine for China’s drug innovation system. Chin J New Drug. 2013;8:868–872. (in Chinese)
   Google Scholar
• G S. Progress of the 2018 national major new medicines developments project and forecast of the 13th five-year plan. China Biotechnol. 2019;2:3–12. (in Chinese)
   Google Scholar
• The Ministry of Science and Technology. Having science and technology playing a key role in defeating the epidemics. Seek Truth 2020;6. (content current as of 2020-03-16). Available from: http://www.qstheory.cn/dukan/qs/2014/2020-03/16/c_1125710486.htm. Accessed 68, 2020. (in Chinese)
   Google Scholar